Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody

Ann Rheum Dis. 2014 Aug;73(8):1591-3. doi: 10.1136/annrheumdis-2014-205278. Epub 2014 Apr 16.

Authors

Jing Zou¹, Ting Li², Xingfang Huang², Sheng Chen², Qiang Guo², Chunde Bao²

Affiliations

¹ Department of Pneumology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
² Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

PMID: 24739327
DOI: 10.1136/annrheumdis-2014-205278

No abstract available

Keywords: Autoimmune Diseases; Dermatomyositis; T Cells.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Autoantibodies / immunology
Basiliximab
DEAD-box RNA Helicases / immunology*
Dermatomyositis / drug therapy*
Dermatomyositis / immunology
Dermatomyositis / mortality
Female
Humans
Immunosuppressive Agents / administration & dosage
Interferon-Induced Helicase, IFIH1
Lung Diseases, Interstitial / drug therapy*
Lung Diseases, Interstitial / immunology
Lung Diseases, Interstitial / mortality
Male
Middle Aged
Recombinant Fusion Proteins / administration & dosage*

Substances

Antibodies, Monoclonal
Autoantibodies
Immunosuppressive Agents
Recombinant Fusion Proteins
Basiliximab
IFIH1 protein, human
DEAD-box RNA Helicases
Interferon-Induced Helicase, IFIH1

Supplementary concepts

Amyopathic dermatomyositis